Virax Biolabs adjourns shareholder meeting after failing to reach quorum

• Virax’s June 5 shareholder meeting was delayed due to a lack of quorum, with 3.6% of eligible shares represented.
• The meeting reconvened June 12; 3.65% of voting shares were present, forming a quorum under the company’s articles.
• Shareholders backed a share consolidation, authorizing a 1-for-10 to 1-for-30 reverse split of ordinary shares.
• Investors also adopted amended and restated memorandum and articles of association to reflect the revised authorized share capital.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Virax Biolabs Group Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-268604), on June 12, 2026, and is solely responsible for the information contained therein.